Authors
Latest:
The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical StudyKira MacDougall, MD, and co-investigators, research the importance of peripheral biomarkers in patients with advanced non–small cell lung cancer who are treated with pembrolizumab.
Latest:
Unmet Needs and Future Perspectives in NSCLC TreatmentThe panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.
Latest:
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer SurvivorshipThe lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.
Latest:
Efficacy and Safety of Zolbetuximab in Gastric CancerZolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Latest:
Samer A. Srour, MB, ChB, MS, Reviewed Findings of CB-NK Cells and Elotuzumab Regimen in High-Risk Multiple MyelomaA phase 2 study investigated the use of cord blood–derived natural killer cells plus elotuzumab, lenalidomide, and melphalan with autologous stem cell transplant for patients with high-risk multiple myeloma.
Latest:
Jeffrey Wolf, MD, on Emerging T-Cell Engagers and Their Impact in Multiple MyelomaThe interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.
Latest:
Decisional Capacity Determination in Patients With CancerExperts discuss the process of assessing decision-making capacity in patients with cancer.
Latest:
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical ProgressionIn the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Latest:
Cross Q&A: Role of Belantamab Mafodotin in MMThe panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
Latest:
How Radiologists Could Use Cryoablation to Put Cancer Pain on IceJ. David Prologo, MD, FSIR, ABOM-D, an interventional radiologist at Emory Healthcare, details how cryoablation can be used by radiologists to manage pain in patients with cancer.
Latest:
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic ReviewDanazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Latest:
Efficacy and Safety of Zolbetuximab in Gastric CancerZolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-USIbrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.
Latest:
Creating a First-of-Its-Kind Integrative Oncology Program at City of HopeEdward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.
Latest:
Oncology-On-The-Go Podcast: Signaling Pathways in Glioblastoma RelapseJavier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.
Latest:
Non-BCMA Targeting Bispecifics in MM and Future Directions in CareBefore closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.
Latest:
Outcomes of Patients on Transplant Waiting Lists: Q&A with Dr. Giancarlo FatobeneThe following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.
